Cardiac Risks With Newer Psoriasis Meds Match TNF Inhibitors
2025年1月7日 · The newer biologics — interleukin (IL)-17, IL-12/23, and IL-23 inhibitors — have cardiovascular safety profiles comparable with those of tumor necrosis factor (TNF) inhibitors in biologic ...
IL-6 Receptor Inhibitors Show Early Promise for CPPD - Medscape
2024年12月20日 · Interleukin 6 receptor (IL-6r) inhibition is a promising approach for the treatment of calcium pyrophosphate deposition disease (CPPD), although no prospective studies have been conducted to date.
JAK Inhibitors, Biologics Show Nuances in RA Pain Outcomes
2024年10月17日 · At 3 months, JAK inhibitors reduced pain scores by 4.0 mm (95% CI, 1.7-6.3) more than TNF inhibitors and by 3.9 mm (95% CI, 0.9-6.9) more than rituximab; however, the change in pain was not ...
Oral IL-23 Inhibitor Calms Moderate to Severe Psoriasis - Medscape
2024年2月7日 · Among 255 patients with plaque psoriasis randomly assigned to receive either placebo or an oral interleukin (IL)–23 receptor antagonist peptide dubbed JNJ-77242113 (Janssen), 79% of those who ...
FDA Approves Two Oral JAK Inhibitors for Atopic Dermatitis
2022年1月14日 · Cite this: FDA Approves Two Oral JAK Inhibitors for Moderate-to-Severe Atopic Dermatitis - Medscape - Jan 14, 2022. Comments 3090D553-9492-4563-8681-AD288FA52ACE
Rituximab and Abatacept May Contribute to Cancer Risk in RA
2024年12月13日 · IL-6 inhibitors showed no significant association with cancer in the primary analysis, but a significantly increased risk was observed in the propensity-matched analysis (HR, 5.65; 95% CI, 1.11-28 ...
Investigative Treatments for Moderate to Severe Psoriasis Reviewed
2025年1月29日 · Icotrokinra, also known as JNJ-77242113, is an oral interleukin (IL)-23 receptor antagonist that is being evaluated for moderate to severe psoriasis in phase 3 trials.
New Molecules Reflect Advances in Atopic Dermatitis - Medscape
2024年1月18日 · Topical formulations of JAK inhibitors could help treat moderate to severe atopic dermatitis in adults and adolescents, said one dermatologist. This site is intended for healthcare professionals ...
Key Data on Psoriatic Arthritis From ACR 2023 - Medscape
2023年12月6日 · Dr Mease opens by reporting on izokibep, a unique interleukin-17A inhibitor. The researchers found that izokibep 80 mg demonstrated high levels of disease control and remained well tolerated at ...
Breaking Rheumatology's Reliance on Steroids: New Strategies
2024年7月25日 · C5a and Interleukin (IL) 6 Receptor Inhibitors as GC-Sparing Drugs. Investigators in a 2021 paper explored whether the C5a receptor inhibitor avacopan could effectively treat patients with ...